BioSpace News Archive

AZD7442 long-acting antibody combination Phase III PROVENT trial prevention data to be presented in late-breaker session

Orthofix Medical Inc today announced that more than 60,000 M6-C ™ artificial cervical discs have been implanted worldwide.

Early Positive Phase 2 efficacy and safety data are both statistically significant and clinically meaningful. No SAE related to Silmitasertib was reported.

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

KemPharm, Inc. today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present at the Benzinga Healthcare Small Cap Conference taking place September 29-30, 2001.

Otonomy, Inc. today announced the presentation of previously disclosed clinical results from the successful OTO-413 Phase 1/2 trial at the upcoming American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS) Annual Meeting to be held in Los Angeles October 3-6, 2021.

9 Meters Biopharma, Inc. today announced a partnership with Mend Hunger, a 501(c)(3) non-profit mobile food pantry organization that serves individuals and families in need of gluten-free food for medical and health reasons.

SmartCella Holding AB, an innovative biotechnology and medtech company, today announces the raising of SEK 328 million to further advance and accelerate the development of core technologies in the company’s three business units, Procella Therapeutics, Smartwise and SvedMed Solutions.

Cidara Therapeutics, Inc. (NASDAQ: CDTX), today announced that it will present new clinical and non-clinical data in three on-demand poster presentations, including data on rezafungin clinical safety and pharmacokinetics in people with hepatic impairment, at IDWeek taking place virtually from September 29-October 3, 2021.

BetterLife Pharma Inc. is pleased to announce it has applied for patent protection of new compositions of 2-bromo-LSD for its use in the treatment of cluster headaches, neuropathic pain and range of mental health conditions, including depression, anxiety and PTSD, and related disorders.